Lundbeck submits European Marketing Authorization Application for nalmefene
Timo Veromaa, Chief Executive Officer of Biotie said, "Filing of Selincro(TM) in Europe is an important step in bringing this novel treatment to patients. Existing drugs for alcohol dependence require abstinence, which is a very high treatment hurdle. Selincro(TM) provides a solution for patients by allowing them to take the drug on an as needed basis, leading to a reduction in their alcohol consumption and number of heavy drinking days."
Lundbeck plans to present efficacy and safety data from its Phase 3 program at the 20th European Congress of Psychiatry (EPA) in Prague, Czech Republic, 3-6 March 2012.